Literature DB >> 33777327

Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions.

Thomas R Fleming1,2, Victor DeGruttola3, Deborah Donnell2.   

Abstract

While much has been achieved, much remains to be accomplished in the science of preventing the spread of HIV infection. Clinical trials that are properly designed, conducted and analyzed are of integral importance in the pursuit of reliable insights about HIV prevention. As we build on previous scientific breakthroughs, there will be an increasing need for clinical trials to be designed to efficiently achieve insights without compromising their reliability and generalizability. Key design features should continue to include: 1) the use of randomization and evidence-based controls, 2) specifying the use of intention-to-treat analyses to preserve the integrity of randomization and to increase interpretability of results, 3) obtaining direct assessments of effects on clinical endpoints such as the risk of HIV infection, 4) using either superiority designs or non-inferiority designs with rigorous non-inferiority margins, and 5) enhancing generalizability through the choice of a relative risk rather than risk difference metric. When interventions have complementary and potentially synergistic effects, factorial designs should be considered to increase efficiency as well as to obtain clinically important insights about interaction and the contribution of component interventions to the efficacy and safety of combination regimens. Key trial conduct issues include timely enrollment of participants at high HIV risk recruited from populations with high viral burden, obtaining 'best real-world achievable' levels of adherence to the interventions being assessed and ensuring high levels of retention. High quality of trial conduct occurs through active rather than passive monitoring, using pre-specified targeted levels of performance with defined methods to achieve those targets. During trial conduct, active monitoring of the performance standards not only holds the trial leaders accountable but also can assist in the development and implementation of creative alternative approaches to increase the quality of trial conduct. Designing, conducting and analyzing HIV prevention trials with the quality needed to obtain reliable insights is an ethical as well as scientific imperative.

Entities:  

Keywords:  factorial designs; hazard ratio; non-inferiority; randomization; relative risks; replacement endpoints

Year:  2019        PMID: 33777327      PMCID: PMC7996711          DOI: 10.1515/scid-2019-0001

Source DB:  PubMed          Journal:  Stat Commun Infect Dis        ISSN: 1948-4690


  42 in total

1.  Some essential considerations in the design and conduct of non-inferiority trials.

Authors:  Thomas R Fleming; Katherine Odem-Davis; Mark D Rothmann; Yuan Li Shen
Journal:  Clin Trials       Date:  2011-08       Impact factor: 2.486

2.  Current issues in non-inferiority trials.

Authors:  Thomas R Fleming
Journal:  Stat Med       Date:  2008-02-10       Impact factor: 2.373

3.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.

Authors:  Jared M Baeten; Thesla Palanee-Phillips; Elizabeth R Brown; Katie Schwartz; Lydia E Soto-Torres; Vaneshree Govender; Nyaradzo M Mgodi; Flavia Matovu Kiweewa; Gonasagrie Nair; Felix Mhlanga; Samantha Siva; Linda-Gail Bekker; Nitesha Jeenarain; Zakir Gaffoor; Francis Martinson; Bonus Makanani; Arendevi Pather; Logashvari Naidoo; Marla Husnik; Barbra A Richardson; Urvi M Parikh; John W Mellors; Mark A Marzinke; Craig W Hendrix; Ariane van der Straten; Gita Ramjee; Zvavahera M Chirenje; Clemensia Nakabiito; Taha E Taha; Judith Jones; Ashley Mayo; Rachel Scheckter; Jennifer Berthiaume; Edward Livant; Cindy Jacobson; Patrick Ndase; Rhonda White; Karen Patterson; Donna Germuga; Beth Galaska; Katherine Bunge; Devika Singh; Daniel W Szydlo; Elizabeth T Montgomery; Barbara S Mensch; Kristine Torjesen; Cynthia I Grossman; Nahida Chakhtoura; Annalene Nel; Zeda Rosenberg; Ian McGowan; Sharon Hillier
Journal:  N Engl J Med       Date:  2016-02-22       Impact factor: 91.245

4.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

Authors: 
Journal:  Control Clin Trials       Date:  1998-02

5.  Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Authors:  Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje
Journal:  N Engl J Med       Date:  2015-02-05       Impact factor: 91.245

6.  An expanded behavioral paradigm for prevention and treatment of HIV-1 infection.

Authors:  Thomas J Coates
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

7.  HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women.

Authors:  M Bradford Guffey; Barbra Richardson; Marla Husnik; Bonus Makanani; David Chilongozi; Elmer Yu; Gita Ramjee; Nyaradzo Mgodi; Kailazarid Gomez; Sharon L Hillier; Salim Abdool Karim
Journal:  Sex Transm Infect       Date:  2014-06-04       Impact factor: 3.519

8.  A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings.

Authors:  Nyaradzo M Mgodi; Simbarashe Takuva; Srilatha Edupuganti; Shelly Karuna; Philip Andrew; Erica Lazarus; Precious Garnett; Emily Shava; Pamela G Mukwekwerere; Nidhi Kochar; Kyle Marshall; Erika Rudnicki; Michal Juraska; Maija Anderson; Carissa Karg; India Tindale; Elizabeth Greene; Nandisile Luthuli; Kagisho Baepanye; John Hural; Margarita M Gomez Lorenzo; David Burns; Maurine D Miner; Julie Ledgerwood; John R Mascola; Deborah Donnell; Myron S Cohen; Lawrence Corey
Journal:  J Acquir Immune Defic Syndr       Date:  2021-05-01       Impact factor: 3.771

9.  Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.

Authors:  Bertran Auvert; Dirk Taljaard; Emmanuel Lagarde; Joëlle Sobngwi-Tambekou; Rémi Sitta; Adrian Puren
Journal:  PLoS Med       Date:  2005-10-25       Impact factor: 11.069

10.  Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study).

Authors:  G Justus Hofmeyr; Charles S Morrison; Jared M Baeten; Tsungai Chipato; Deborah Donnell; Peter Gichangi; Nelly Mugo; Kavita Nanda; Helen Rees; Petrus Steyn; Douglas Taylor
Journal:  Gates Open Res       Date:  2018-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.